CONCLUSIONS
In conclusion, we found that disparities in reporting and participation of minority racial groups continue to exist. We believe that requiring reporting of patient demographic data in clinical trials, in compliance with the NIH Revitalization Act, will improve transparency and the rate of reporting. Furthermore, it will critically inform health policymakers and other stakeholders to address the root causes of the underrepresentation of minorities by addressing social barriers and hesitancy to participate in clinical trials.